Efficacy and safety of edoxaban for treatment of venous thromboembolism: A subanalysis of East Asian patients in the Hokusai-VTE trial

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 9, 2015, Pages 1606-1614

  Nakamura, M ^a   Wang, Y Q ^b   Wang, C ^c,d   Oh, D ^e   Yin, W H ^f,g   Kimura, T ^h   Miyazaki, K ^h   Abe, K ^h   Mercuri, M ⁱ   Lee, L H ^j   Segers, A ^k   Buller H ^l  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUDAN UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e CHA University   (South Korea)

^f CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h DAIICHI SANKYO CO   (Japan)

ⁱ DAIICHI SANKYO INC   (United States)

^j SINGAPORE GENERAL HOSPITAL   (Singapore)

^k ITREAS   (Netherlands)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

Edoxaban; Safety; Treatment efficacy; Venous thromboembolism; Warfarin

Indexed keywords

EDOXABAN; HEPARIN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHINA; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EAST ASIAN; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; JAPAN; KOREA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TAIWAN; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; ETHNOLOGY; FAR EAST; FOLLOW UP; MORTALITY; PULMONARY EMBOLISM; THERAPEUTIC EQUIVALENCE; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FAR EAST; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; PYRIDINES; RECURRENCE; THERAPEUTIC EQUIVALENCY; THIAZOLES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMIN K; WARFARIN; YOUNG ADULT;

EID: 84940900695     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13055     Document Type: Article

References (21)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
2. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-46.
3. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, Becker RC, Goldberg RJ. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7.
4. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64.
5. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
6. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011; 9: 85-91.
7. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010; 8: 1515-23.
8. Liu HS, Kho BC, Chan JC, Cheung FM, Lau KY, Choi FP, Wu WC, Yau TK. Venous thromboembolism in the Chinese population - experience in a regional hospital in Hong Kong. Hong Kong Med J 2002; 8: 400-5.
9. Japanese Circulation Society Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011; 75: 1258-81.
10. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-15.
11. Ayala C, Croft JB, Greenlund KJ, Keenan NL, Donehoo RS, Malarcher AM, Mensah GA. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995-1998. Stroke 2002; 33: 1197-201.
12. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-97.
13. Bang OY, Hong KS, Heo JH, Koo J, Kwon SU, Yu KH, Bae HJ, Lee BC, Yoon BW, Kim JS. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke 2014; 16: 73-80.
14. The Hokusai VTE Investigators, Büller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-15.
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
16. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-6.
17. Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, Breithardt G, Mahaffey KW, Becker RC, Califf R, Fox KA, Berkowitz SD, Hacke W, Hankey GJ; Executive Steering Committee and the ROCKET AF Study Investigators. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014; 45: 1739-47.
18. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
19. Lertkiatmongkol P, Assawamakin A, White G, Chopra G, Rongnoparut P, Samudrala R, Tongsima S. Distal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarin. PLoS ONE 2013; 8: e74053.
20. van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012; 126: 2309-16.
21. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-7.